Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Cahn, Pedro; Pozniak, Anton; Mingrone, Horacio; A Shuldyakov, А; Brites, Carlos; Andrade‐Villanueva, Jaime; Richmond, Gary; Beltran Buendia, Carlos; Fourie, Jan; Ramgopal, Moti; Hagins, Debbie; Felizarta, Franco; Valdez Madruga, José; Reuter, Tânia; Newman, Tâmara; B. Small, Catherine; Lombaard, John; Grinsztejn, Beatriz; Dorey, David; Underwood, Mark; Griffith, Sandy; Min, Sherene

doi:10.1016/s0140-6736(13)61221-0

Public

Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study

Published in The Lancet • Jul 3, 2013

Authors:

Pedro Cahn

Anton Pozniak

Horacio Mingrone

Abstract

BACKGROUND: Dolutegravir (GSK1349572), a once-daily HIV integrase inhibitor, has shown potent antiviral response and a favourable safety profile. We evaluated safety, efficacy, and emergent resistance in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV-1 with at least two-class ...

Subject

Raltegravir

Dolutegravir

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!